Literature DB >> 28139933

Functionalized Triblock Copolymer Vectors for the Treatment of Acute Lymphoblastic Leukemia.

Robert C Deller1, Paraskevi Diamanti1,2, Gabriella Morrison1, James Reilly1, Benjamin C Ede1, Robert Richardson3, Kristian Le Vay4,5, Andrew M Collins3,5, Allison Blair1,2, Adam W Perriman1.   

Abstract

The chemotherapeutic Parthenolide is an exciting new candidate for the treatment of acute lymphoblastic leukemia, but like many other small-molecule drugs, it has low aqueous solubility. As a consequence, Parthenolide can only be administered clinically in the presence of harmful cosolvents. Accordingly, we describe the synthesis, characterization, and testing of a range of biocompatible triblock copolymer micelles as particle-based delivery vectors for the hydrophobic drug Parthenolide. The drug-loaded particles are produced via an emulsion-to-micelle transition method, and the effects of introducing anionic and cationic surface charges on stability, drug sequestration, biocompatibility, and efficacy are investigated. Significantly, we demonstrate high levels of efficacy in the organic solvent-free systems against human mesenchymal stem cells and primary T-acute lymphoblastic leukemia patient cells, highlighting the effectiveness of the delivery vectors for the treatment of acute lymphoblastic leukemia.

Entities:  

Keywords:  acute lymphoblastic leukemia (ALL); micelle; nanoparticle; parthenolide; pluronic; poloxamer

Mesh:

Substances:

Year:  2017        PMID: 28139933     DOI: 10.1021/acs.molpharmaceut.6b01008

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  2 in total

Review 1.  The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy.

Authors:  Tao An; Huanhuan Yin; Yanting Lu; Feng Liu
Journal:  Drug Des Devel Ther       Date:  2022-04-29       Impact factor: 4.319

2.  Investigating chemoresistance to improve sensitivity of childhood T-cell acute lymphoblastic leukemia to parthenolide.

Authors:  Benjamin C Ede; Rafal R Asmaro; John P Moppett; Paraskevi Diamanti; Allison Blair
Journal:  Haematologica       Date:  2018-05-17       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.